Tags

Type your tag names separated by a space and hit enter

The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics.
J Asthma. 2003 May; 40(3):257-64.JA

Abstract

Thromboxane A2 (TXA2), an arachidonate derivative, is a potent bronchoconstrictor; therefore, blocking TXA2 should attenuate airway narrowing. Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic. It was reported that seratrodast reduced bronchial hyperresponsiveness. However, it is controversial whether it reduces airway inflammation. We studied some additional effects of oral seratrodast to inhaled corticosteroids on 10 adult asthmatics in an open-label, crossover design study. Eosinophil cationic protein (ECP) levels in serum and sputum, peak expiratory flow rate (PEF), clinical symptoms, and airway responsiveness were evaluated. Clinical symptom scores were improved by administration of seratrodast (p < 0.05). The addition of seratrodast to asthmatic patients significantly improved mean PEF (p < 0.05). In addition, withdrawal of seratrodast resulted in deterioration of PEF. Airway hyperresponsiveness to acetylcholine measured by Astograph was improved by administration of seratrodast (p < 0.01), and returned to the level of "run-in period" after withdrawal. Administration of seratrodast decreased the concentration of ECP in sputum significantly (p < 0.05), and sputum ECP significantly increased again after withdrawal of (p < 0.05). These results suggest that seratrodast improves clinical symptoms andairway hyperresponsiveness by reducing airway inflammation. Seratrodast may be useful as an anti-inflammatory agent and beneficial when added to inhaled corticosteroids in the treatment of bronchial asthma.

Authors+Show Affiliations

The Pulmonary Medicine, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12807169

Citation

Fukuoka, Toshihiko, et al. "The Effect of Seratrodast On Eosinophil Cationic Protein and Symptoms in Asthmatics." The Journal of Asthma : Official Journal of the Association for the Care of Asthma, vol. 40, no. 3, 2003, pp. 257-64.
Fukuoka T, Miyake S, Umino T, et al. The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. J Asthma. 2003;40(3):257-64.
Fukuoka, T., Miyake, S., Umino, T., Inase, N., Tojo, N., & Yoshizawa, Y. (2003). The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 40(3), 257-64.
Fukuoka T, et al. The Effect of Seratrodast On Eosinophil Cationic Protein and Symptoms in Asthmatics. J Asthma. 2003;40(3):257-64. PubMed PMID: 12807169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics. AU - Fukuoka,Toshihiko, AU - Miyake,Shuji, AU - Umino,Takeshi, AU - Inase,Naohiko, AU - Tojo,Naoko, AU - Yoshizawa,Yasuyuki, PY - 2003/6/17/pubmed PY - 2003/7/2/medline PY - 2003/6/17/entrez SP - 257 EP - 64 JF - The Journal of asthma : official journal of the Association for the Care of Asthma JO - J Asthma VL - 40 IS - 3 N2 - Thromboxane A2 (TXA2), an arachidonate derivative, is a potent bronchoconstrictor; therefore, blocking TXA2 should attenuate airway narrowing. Seratrodast, a TXA2 receptor antagonist, is expected to be a potent antiasthmatic. It was reported that seratrodast reduced bronchial hyperresponsiveness. However, it is controversial whether it reduces airway inflammation. We studied some additional effects of oral seratrodast to inhaled corticosteroids on 10 adult asthmatics in an open-label, crossover design study. Eosinophil cationic protein (ECP) levels in serum and sputum, peak expiratory flow rate (PEF), clinical symptoms, and airway responsiveness were evaluated. Clinical symptom scores were improved by administration of seratrodast (p < 0.05). The addition of seratrodast to asthmatic patients significantly improved mean PEF (p < 0.05). In addition, withdrawal of seratrodast resulted in deterioration of PEF. Airway hyperresponsiveness to acetylcholine measured by Astograph was improved by administration of seratrodast (p < 0.01), and returned to the level of "run-in period" after withdrawal. Administration of seratrodast decreased the concentration of ECP in sputum significantly (p < 0.05), and sputum ECP significantly increased again after withdrawal of (p < 0.05). These results suggest that seratrodast improves clinical symptoms andairway hyperresponsiveness by reducing airway inflammation. Seratrodast may be useful as an anti-inflammatory agent and beneficial when added to inhaled corticosteroids in the treatment of bronchial asthma. SN - 0277-0903 UR - https://www.unboundmedicine.com/medline/citation/12807169/The_effect_of_seratrodast_on_eosinophil_cationic_protein_and_symptoms_in_asthmatics_ L2 - http://www.tandfonline.com/doi/full/10.1081/jas-120018322 DB - PRIME DP - Unbound Medicine ER -